William E L Ormiston1,2, Hooman Yarmohammadi1, Stephanie Lobaugh3, Juliana Schilsky1, Seth S Katz1, Maria LaGratta1, Sara Velayati1, Junting Zheng3, Marinela Capanu3, Richard K G Do4. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-276F, New York, NY, 10065, USA. 2. Department of Radiology, Auckland City Hospital, Auckland, New Zealand. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-276F, New York, NY, 10065, USA. dok@mskcc.org.
Abstract
PURPOSE: The LI-RADS Treatment Response (LR-TR) algorithm was introduced in 2017 to assist radiologists in assessing hepatocellular carcinoma (HCC) response following locoregional therapy. The objective of this study was to evaluate the associations between pre-treatment LI-RADS diagnostic categories, post-treatment LR-TR categories, and mRECIST response categories with overall survival (OS) of patients with HCC. METHODS: This retrospective study included untreated patients with one or two lesions who underwent transarterial embolization with or without concomitant ablation from December 2003 to December 2017. Two radiologists (R1 and R2) reviewed pre- and post-treatment CT imaging. Associations between pre- and post-treatment variables, including post-treatment LR-TR categories (Viable, Equivocal, Nonviable), with OS were assessed using the Kaplan-Meier method and Cox proportional hazards regression. RESULTS: Eighty-five patients were included (median age = 71 years, range 50-87; 17 women). The median OS from first embolization was 43.92 months. Pre- and post-treatment tumor size, pre-treatment LR-TIV (compared with LR-5), and post-treatment LR-TR Viable (compared with LR-TR Nonviable) were associated with OS (p < 0.05 for all). Median OS was shorter for LR-TR Viable patients (R1, 25.64 months, 95% CI 18.58-35.70; R2, 26.43 months 95% CI 20.68-43.92) than for LR-TR Nonviable patients (64.21 months R1 and R2, 95% CI 42.71-92.45 and 36.30-94.09, respectively). mRECIST categories showed similar associations with OS. Inter-reader agreement was moderate for LI-RADS categories (κ = 0.57, 95% CI 0.35-0.78) and substantial for LR-TR categories (κ = 0.68, 95% CI 0.55-0.81). CONCLUSIONS: LR-TR categories show a strong association with OS in HCC patients treated with transarterial embolization.
PURPOSE: The LI-RADS Treatment Response (LR-TR) algorithm was introduced in 2017 to assist radiologists in assessing hepatocellular carcinoma (HCC) response following locoregional therapy. The objective of this study was to evaluate the associations between pre-treatment LI-RADS diagnostic categories, post-treatment LR-TR categories, and mRECIST response categories with overall survival (OS) of patients with HCC. METHODS: This retrospective study included untreated patients with one or two lesions who underwent transarterial embolization with or without concomitant ablation from December 2003 to December 2017. Two radiologists (R1 and R2) reviewed pre- and post-treatment CT imaging. Associations between pre- and post-treatment variables, including post-treatment LR-TR categories (Viable, Equivocal, Nonviable), with OS were assessed using the Kaplan-Meier method and Cox proportional hazards regression. RESULTS: Eighty-five patients were included (median age = 71 years, range 50-87; 17 women). The median OS from first embolization was 43.92 months. Pre- and post-treatment tumor size, pre-treatment LR-TIV (compared with LR-5), and post-treatment LR-TR Viable (compared with LR-TR Nonviable) were associated with OS (p < 0.05 for all). Median OS was shorter for LR-TR Viable patients (R1, 25.64 months, 95% CI 18.58-35.70; R2, 26.43 months 95% CI 20.68-43.92) than for LR-TR Nonviable patients (64.21 months R1 and R2, 95% CI 42.71-92.45 and 36.30-94.09, respectively). mRECIST categories showed similar associations with OS. Inter-reader agreement was moderate for LI-RADS categories (κ = 0.57, 95% CI 0.35-0.78) and substantial for LR-TR categories (κ = 0.68, 95% CI 0.55-0.81). CONCLUSIONS: LR-TR categories show a strong association with OS in HCC patients treated with transarterial embolization.
Authors: Khaled M Elsayes; Jonathan C Hooker; Michelle M Agrons; Ania Z Kielar; An Tang; Kathryn J Fowler; Victoria Chernyak; Mustafa R Bashir; Yuko Kono; Richard K Do; Donald G Mitchell; Aya Kamaya; Elizabeth M Hecht; Claude B Sirlin Journal: Radiographics Date: 2017 Nov-Dec Impact factor: 5.333
Authors: Ahsun Riaz; Ahmed Gabr; Nadine Abouchaleh; Rehan Ali; Ali Al Asadi; Ronald Mora; Laura Kulik; Kush Desai; Bartley Thornburg; Samdeep Mouli; Ryan Hickey; Frank H Miller; Vahid Yaghmai; Daniel Ganger; Robert J Lewandowski; Riad Salem Journal: Hepatology Date: 2018-01-26 Impact factor: 17.425
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Karen T Brown; Richard K Do; Mithat Gonen; Anne M Covey; George I Getrajdman; Constantinos T Sofocleous; William R Jarnagin; Michael I D'Angelica; Peter J Allen; Joseph P Erinjeri; Lynn A Brody; Gerald P O'Neill; Kristian N Johnson; Alessandra R Garcia; Christopher Beattie; Binsheng Zhao; Stephen B Solomon; Lawrence H Schwartz; Ronald DeMatteo; Ghassan K Abou-Alfa Journal: J Clin Oncol Date: 2016-02-01 Impact factor: 44.544
Authors: Erin L Shropshire; Mohammad Chaudhry; Chad M Miller; Brian C Allen; Erol Bozdogan; Diana M Cardona; Lindsay Y King; Gemini L Janas; Richard K Do; Charles Y Kim; James Ronald; Mustafa R Bashir Journal: Radiology Date: 2019-04-30 Impact factor: 29.146
Authors: Bruno Vincenzi; Massimo Di Maio; Marianna Silletta; Loretta D'Onofrio; Chiara Spoto; Maria Carmela Piccirillo; Gennaro Daniele; Francesca Comito; Eliana Maci; Giuseppe Bronte; Antonio Russo; Daniele Santini; Francesco Perrone; Giuseppe Tonini Journal: PLoS One Date: 2015-07-31 Impact factor: 3.240
Authors: Mishal Mendiratta-Lala; Anum Aslam; Katherine E Maturen; Maria Westerhoff; Chris Maurino; Neehar D Parikh; Yilun Sun; Christopher J Sonnenday; Erica B Stein; Kimberly L Shampain; Ravi K Kaza; Kyle Cuneo; William Masch; Richard Kinh Gian Do; Theodore S Lawrence; Dawn Owen Journal: Int J Radiat Oncol Biol Phys Date: 2021-10-10 Impact factor: 8.013